FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889357501> ?p ?o ?g. }

• W2889357501 endingPage "264" @default.
• W2889357501 startingPage "1" @default.
• W2889357501 abstract "Ovarian cancer is the sixth most common cancer in UK women and can be difficult to diagnose, particularly in the early stages. Risk-scoring can help to guide referral to specialist centres.To assess the clinical and cost-effectiveness of risk scores to guide referral decisions for women with suspected ovarian cancer in secondary care.Twenty-one databases, including MEDLINE and EMBASE, were searched from inception to November 2016. Review methods followed published guidelines. The meta-analysis using weighted averages and random-effects modelling was used to estimate summary sensitivity and specificity with 95% confidence intervals (CIs). The cost-effectiveness analysis considered the long-term costs and quality-adjusted life-years (QALYs) associated with different risk-scoring methods, and subsequent care pathways. Modelling comprised a decision tree and a Markov model. The decision tree was used to model short-term outcomes and the Markov model was used to estimate the long-term costs and QALYs associated with treatment and progression.Fifty-one diagnostic cohort studies were included in the systematic review. The Risk of Ovarian Malignancy Algorithm (ROMA) score did not offer any advantage over the Risk of Malignancy Index 1 (RMI 1). Patients with borderline tumours or non-ovarian primaries appeared to account for disproportionately high numbers of false-negative, low-risk ROMA scores. (Confidential information has been removed.) To achieve similar levels of sensitivity to the Assessment of Different NEoplasias in the adneXa (ADNEX) model and the International Ovarian Tumour Analysis (IOTA) group's simple ultrasound rules, a very low RMI 1 decision threshold (25) would be needed; the summary sensitivity and specificity estimates for the RMI 1 at this threshold were 94.9% (95% CI 91.5% to 97.2%) and 51.1% (95% CI 47.0% to 55.2%), respectively. In the base-case analysis, RMI 1 (threshold of 250) was the least effective [16.926 life-years (LYs), 13.820 QALYs] and the second cheapest (£5669). The IOTA group's simple ultrasound rules (inconclusive, assumed to be malignant) were the cheapest (£5667) and the second most effective [16.954 LYs, 13.841 QALYs], dominating RMI 1. The ADNEX model (threshold of 10%), costing £5699, was the most effective (16.957 LYs, 13.843 QALYs), and compared with the IOTA group's simple ultrasound rules, resulted in an incremental cost-effectiveness ratio of £15,304 per QALY gained. At thresholds of up to £15,304 per QALY gained, the IOTA group's simple ultrasound rules are cost-effective; the ADNEX model (threshold of 10%) is cost-effective for higher thresholds.Information on the downstream clinical consequences of risk-scoring was limited.Both the ADNEX model and the IOTA group's simple ultrasound rules may offer increased sensitivity relative to current practice (RMI 1); that is, more women with malignant tumours would be referred to a specialist multidisciplinary team, although more women with benign tumours would also be referred. The cost-effectiveness model supports prioritisation of sensitivity over specificity. Further research is needed on the clinical consequences of risk-scoring.This study is registered as PROSPERO CRD42016053326.The National Institute for Health Research Health Technology Assessment programme." @default.
• W2889357501 created "2018-09-07" @default.
• W2889357501 creator A5021404933 @default.
• W2889357501 creator A5046117013 @default.
• W2889357501 creator A5053224823 @default.
• W2889357501 creator A5057351979 @default.
• W2889357501 creator A5059685514 @default.
• W2889357501 creator A5065584931 @default.
• W2889357501 creator A5065740152 @default.
• W2889357501 creator A5066388523 @default.
• W2889357501 creator A5074205715 @default.
• W2889357501 date "2018-08-01" @default.
• W2889357501 modified "2023-10-14" @default.
• W2889357501 title "Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis" @default.
• W2889357501 cites W1186458034 @default.
• W2889357501 cites W1589127617 @default.
• W2889357501 cites W1594588774 @default.
• W2889357501 cites W160481027 @default.
• W2889357501 cites W1606812764 @default.
• W2889357501 cites W1747791528 @default.
• W2889357501 cites W1756193797 @default.
• W2889357501 cites W1783762155 @default.
• W2889357501 cites W1874655028 @default.
• W2889357501 cites W1883374220 @default.
• W2889357501 cites W1896219642 @default.
• W2889357501 cites W1944723793 @default.
• W2889357501 cites W1968939401 @default.
• W2889357501 cites W1980181125 @default.
• W2889357501 cites W1985600698 @default.
• W2889357501 cites W1988092700 @default.
• W2889357501 cites W1990396265 @default.
• W2889357501 cites W1993521123 @default.
• W2889357501 cites W1998904023 @default.
• W2889357501 cites W2007220222 @default.
• W2889357501 cites W2014441819 @default.
• W2889357501 cites W2015113538 @default.
• W2889357501 cites W2020488794 @default.
• W2889357501 cites W2027934461 @default.
• W2889357501 cites W2029630138 @default.
• W2889357501 cites W2037421127 @default.
• W2889357501 cites W2040336929 @default.
• W2889357501 cites W2043621331 @default.
• W2889357501 cites W2051347484 @default.
• W2889357501 cites W2051570641 @default.
• W2889357501 cites W2051575509 @default.
• W2889357501 cites W2056110692 @default.
• W2889357501 cites W2057423894 @default.
• W2889357501 cites W2060104329 @default.
• W2889357501 cites W2064507327 @default.
• W2889357501 cites W2066315241 @default.
• W2889357501 cites W2071020286 @default.
• W2889357501 cites W2072942199 @default.
• W2889357501 cites W2075536312 @default.
• W2889357501 cites W2080203245 @default.
• W2889357501 cites W2087409742 @default.
• W2889357501 cites W2089650833 @default.
• W2889357501 cites W2096341530 @default.
• W2889357501 cites W2097907626 @default.
• W2889357501 cites W2099241197 @default.
• W2889357501 cites W2099878111 @default.
• W2889357501 cites W2102306754 @default.
• W2889357501 cites W2102371025 @default.
• W2889357501 cites W2106010518 @default.
• W2889357501 cites W2107638293 @default.
• W2889357501 cites W2108582222 @default.
• W2889357501 cites W2116308061 @default.
• W2889357501 cites W2121127837 @default.
• W2889357501 cites W2122317738 @default.
• W2889357501 cites W2124344335 @default.
• W2889357501 cites W2126233390 @default.
• W2889357501 cites W2126727011 @default.
• W2889357501 cites W2126747154 @default.
• W2889357501 cites W2131668157 @default.
• W2889357501 cites W2131753057 @default.
• W2889357501 cites W2134513531 @default.
• W2889357501 cites W2138664471 @default.
• W2889357501 cites W2150111492 @default.
• W2889357501 cites W2150450484 @default.
• W2889357501 cites W2153788225 @default.
• W2889357501 cites W2163983250 @default.
• W2889357501 cites W2169160087 @default.
• W2889357501 cites W2186152071 @default.
• W2889357501 cites W2222529560 @default.
• W2889357501 cites W2225532266 @default.
• W2889357501 cites W2261304356 @default.
• W2889357501 cites W2282592240 @default.
• W2889357501 cites W2295797365 @default.
• W2889357501 cites W2302838500 @default.
• W2889357501 cites W2311097689 @default.
• W2889357501 cites W2322406439 @default.
• W2889357501 cites W2387187242 @default.
• W2889357501 cites W2414359398 @default.
• W2889357501 cites W2414635861 @default.
• W2889357501 cites W2419151597 @default.
• W2889357501 cites W2460840360 @default.
• W2889357501 cites W2461173513 @default.
• W2889357501 cites W2470985234 @default.
• W2889357501 cites W2487563357 @default.

• next